A5101921480- Pharmacogenetics and Drug Metabolism
- PI3K/AKT/mTOR signaling in cancer
- Chronic Lymphocytic Leukemia Research
- Cancer-related molecular mechanisms research
- Melanoma and MAPK Pathways
- Biochemical and Molecular Research
- Cancer therapeutics and mechanisms
- MicroRNA in disease regulation
- HER2/EGFR in Cancer Research
- Diabetes Treatment and Management
- Pancreatic function and diabetes
- RNA regulation and disease
- Pharmacological Effects of Natural Compounds
- Computational Drug Discovery Methods
- Toxin Mechanisms and Immunotoxins
- Advanced battery technologies research
- Synthesis and biological activity
- Gastrointestinal Tumor Research and Treatment
- Neuroendocrine Tumor Research Advances
- Chemical Reactions and Isotopes
- Connective Tissue Growth Factor Research
- Circular RNAs in diseases
- Gut microbiota and health
- RNA Research and Splicing
- Advanced Battery Materials and Technologies
Shenyang Pharmaceutical University
2024-2025
Amgen (United States)
2025
Southern Medical University
2023-2024
Nanfang Hospital
2023-2024
Dalian University of Technology
2020-2024
Dalian University
2019-2022
Kanazawa University
2019
Affiliated Zhongshan Hospital of Dalian University
2019
Introduction The gut microbiota (GM) influences the occurrence and progression of lung cancer (LC), with potential involvement immune cells (IC). We aimed to investigate causal impact GM on LC identify cell mediators. Methods utilized data for Genome-Wide Association Studies (GWAS) were summarized as follows: from Dutch Microbiome Project (DMP) ( N = 7,738), Transdisciplinary Research in Cancer Lung (TRICL) International Consortium (ILCCO) case 29,266, control 56,450) included four types...
Abstract Nasopharyngeal carcinoma (NPC) is a common cancer found in the nasopharynx, which plagues countless NPC patients. MicroRNA‐372 (miR‐372) has been reported to be involved various tumors. Here, we explored important role of miR‐372 radiosensitivity, invasion, and metastasis NPC. Microarray analysis was conducted search NPC‐related differentially expressed genes (DEGs) predict miRs regulating PBK, suggested that could influence development via PBK p53 signaling pathway. Importantly,...
Enrichment of Veillonella parvula in the lung microbiota is strongly associated with non-small cell cancer (NSCLC) and induces progression adenocarcinoma vivo, but its actual role mechanism remain unexplored. This study analyzed correlation between NSCLC V. abundance based on 16 s rRNA sequencing results. The effects were observed vivo vitro using a C57 bl/6j mouse tumor-bearing model, bacterial co-culture combined transcriptome sequencing, TCGA database to explore validate growth promotion...
Cancer therapy with tyrosine kinase inhibitors (TKIs) is a rapidly developing field, and several TKIs have been reported to an impact on the activities of UDP-glucosyltransferases (UGTs), implying potential risk for drug-drug interaction (DDI). Herein, we investigated inhibitory effects two commonly used TKIs, midostaurin ruxolitinib, human UGTs quantitatively evaluated their DDI via UGT inhibition. It was found that potent inhibitor majority UGTs, including UGT1A3, 1A4, 1A7, 1A8, 1A9, 1A10,...
Dabrafenib is a novel small molecule tyrosine kinase inhibitor (TKI) which used to treat metastatic melanoma. The aim of this research was survey the effects dabrafenib on human UDP-glucuronosyltransferases (UGTs) and evaluate risk drug-drug interactions (DDIs). formation rates for 4-methylumbelliferone (4-MU) glucuronide trifluoperazine-glucuronide in 12 recombinant UGT isoforms with or without were measured HPLC investigate inhibitory UGTs. Inhibition kinetic studies also conducted. In...
Cabozantinib is a multiple receptor tyrosine kinases inhibitor (TKI) approved to treat progressive, metastatic medullary thyroid cancer, advanced renal cell carcinoma, and hepatocellular carcinoma. Drugdrug interactions (DDIs) for cabozantinib have been identified involving the role of cytochromes P450. Although previous study reported that showed slight inhibition UDP-glucuronosyltransferase (UGT) 1A1 at highest concentration tested, there are no reports on potential UGTs-mediated-DDIs....
Background: Avapritinib is the only drug for adult patients with PDGFRA exon 18 mutated unresectable or metastatic gastrointestinal stromal tumor (GIST). Although avapritinib has been approved by FDA four years, little known about risk of drug-drug interac-tions (DDIs) via UDP-glucuronyltransferases (UGTs) inhibition. Objective: The aim present study was to systematically evaluate inhibitory effects against UGTs and quantitatively estimate its potential DDIs in vivo. Methods: Recombinant...